PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space by Michael E. Cloesmeijer, Erik Sjögren, Sjoerd F. Koopman, Peter. J. Lenting, Marjon H. Cnossen, Ron A. A. Mathôt, the OPTI‐CLOT study group and SYMPHONY consortium

Get full text

Replacement therapy in pregnant women with von Willebrand disease during delivery: Factor levels and pharmacokinetics by Wala Al Arashi, Michael E. Cloesmeijer, Frank W. G. Leebeek, Johannes J. Duvekot, Marieke J. H. A. Kruip, Ron A. A. Mathôt, Marjon H. Cnossen, the OPTI‐CLOT/To WiN study group and SYMPHONY consortium

Get full text

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis by Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van derPlas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink

Get full text

Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-... by Lotte Haverman, Ron A A Mathôt, Floor Veltkamp, Djera H Khan, Christa Reefman, Susan Veissi, Hedy A van Oers, Elena Levtchenko, Sandrine Florquin, Joanna A E van Wijk, Michiel F Schreuder, Antonia H M Bouts

Get full text

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the... by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek

Get full text